Our Equity Story

Imlifdase – a novel approach to eliminate pathogenic IgG

Imlifidase's mode of action

Imlifidase’s Mode of Action is that it cleaves IgG within 2-6 hours from a 15-minute infusion, IgG levels will then drop to below detectable levels and stay supressed for approximately 5-7 days, before it gradually returns back to normal levels.

 

Potential indication universe

Potential Indication Universe

Beyond kidney transplantation, imlifidase could potentially be used in post-transplantation and transplantation of other organs, as a treatment for acute autoimmune diseases and as a pre-treatment for gene therapy.

Additionally, Hansa is developing a next generation of enzymes under the program NiceR for repeat dosing administration. The NiceR program will potentially open a very large universe of potential indications, including a number of gene therapy programs, autoimmune diseases and oncology.

 

Our Business Model

Technology platform

In transplantation and autoimmune diseases, Hansa Biopharma intends utilize its own commercial infrastructure, utilizing inhouse capabilities from an experienced and skilled team to secure a successfully entry into these markets. In other areas where the market overall is more complex and fragmented, such as gene therapy and oncology, Hansa will consider alternative pathways for commercial success. In these markets, Hansa may employ a partnering strategy similar to the agreement with Sarepta Therapeutics in gene therapy.

 

Our Strategic Priorities

Our strategic priorities

 

Our development programs

Our development programs

 

Our mid-term financial priorities

Our mid-term financial priorities

Hansa’s key midterm financial priorities will be focused on securing a successful European launch as well as commercially expand across larger European markets, while targeting satisfactory product profitability in Europe.

Secondly, the Company wish to further strengthen the position and expansion in kidney transplantation as Hansa approach a potential market approval in the U.S.

Thirdly the Company anticipate accelerating its activities in areas such as autoimmunity, gene therapy and oncology. Lastly, Hansa wish to continue to engage in more potential partnerships in both gene therapy and oncology as well as into technology areas, where it potentially makes senses to build develop combination therapies.